LAWRENCE KENNARD: Open Payments
NPI 1558872531 · NEWPORT, TN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,048 in 56 payments from 24 companies in 2025. Trend: 2023 $73 · 2024 $0 · 2025 $1,048
Food & beverage: $1,048
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 9 | $164 |
| Neurocrine BioSciences, Inc. | 5 | $94 |
| Lundbeck LLC | 4 | $80 |
| Astellas Pharma US Inc | 3 | $75 |
| Corcept Therapeutics | 4 | $70 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $66 |
| Sumitomo Pharma America, Inc. | 3 | $48 |
| Otsuka America Pharmaceutical, Inc. | 3 | $47 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $45 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $37 |
Products named: REXULTI, FARXIGA, INGREZZA, Veozah, Korlym, Kerendia, GEMTESA, XIFAXAN.
Industry payments across TN — which companies pay providers there.
